Guggenheim raised the firm’s price target on Verve Therapeutics (VERV) to $24 from $18 and keeps a Buy rating on the shares, arguing that the top-line Heart-2 Phase 1b data for VERVE-102 “provided a strikingly clean win.” Following the data, the firm is increasing its view on the odds of success to 75% from 60%, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Cantor upgrades Verve Therapeutics to Overweight after positive data
- Verve Therapeutics price target raised to $39 from $32 at Canaccord
- Verve Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- Verve Therapeutics price target raised to $25 from $15 at H.C. Wainwright
- Buy Rating for Verve Therapeutics: Promising Safety and Efficacy of VERVE-102 in Phase 1b Heart-2 Study